Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan Y Yu

Showing results (141-150 of 234) with videos related to

Pageof 24
Sort By:
Clinical Genitourinary Cancer|March 8, 2020
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional StudyMarco Bandini, Filippo Pederzoli, Russell Madison, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.
Cancer Medicine|December 22, 2016
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survivalJorge D Ramos, Martin F Casey, Simon J Crabb, et al.
Clinical Genitourinary Cancer|December 14, 2020
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy RegimensOlivia A Do, Lorin A Ferris, Sarah K Holt, et al.
Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.
Pageof 24

Showing results (141-150 of 234) with videos related to

Sort By:
Pageof 24
Clinical Genitourinary Cancer|March 8, 2020
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional StudyMarco Bandini, Filippo Pederzoli, Russell Madison, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
The Oncologist|April 3, 2019
The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract CancerAristotelis Bamias, Kimon Tzannis, Christina Bamia, et al.
Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Cancer|May 8, 2014
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaMaha Hussain, Stephanie Daignault, Neeraj Agarwal, et al.
Clinical Genitourinary Cancer|January 29, 2023
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder CancerDimitrios Makrakis, Jonathan L Wright, Martine P Roudier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate CancerEvan Y Yu, Hongli Li, Celestia S Higano, et al.
Cancer Medicine|December 22, 2016
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survivalJorge D Ramos, Martin F Casey, Simon J Crabb, et al.
Clinical Genitourinary Cancer|December 14, 2020
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy RegimensOlivia A Do, Lorin A Ferris, Sarah K Holt, et al.
Cancer|April 16, 2015
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancerMatthew D Galsky, Sumanta K Pal, Simon Chowdhury, et al.
Pageof 24